Navigation Links
Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
Date:8/5/2008

LEXINGTON, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced its consolidated results of operations for the third quarter ended June 30, 2008. The Company will host a conference call and webcast today beginning at 9:00 am eastern time (details follow below).

The Company reported revenues of $20.4 million and a consolidated net loss of $19.0 million or $0.25 per share for the quarter ended June 30, 2008. This compares to revenues of $12.2 million and a consolidated net loss of $72.3 million or $1.02 per share for the quarter ended June 30, 2007. During the quarter ended June 30, 2008, the Company reported a restructuring charge of approximately $3.5 million. During the quarter ended June 30, 2007, the Company incurred one time charges of $53.3 million related to the acquisition of Valera Pharmaceuticals which was completed on April 18, 2007.

For the nine months ended June 30, 2008, the Company reported revenues of $54.5 million and a consolidated net loss of $51.6 million or $0.67 per share compared to revenues of $36.6 million and a consolidated net loss of $95.1 million or $1.56 per share for the nine months ended June 30, 2007.

At June 30, 2008, the Company had consolidated cash and cash equivalents totaling approximately $52.6 million.

"This has been a very active and eventful quarter for the Company," said Glenn L. Cooper, chairman and chief executive officer of Indevus. "Obviously, we are very disappointed in the FDA's decision to issue an approvable letter for NEBIDO(R). This certainly was not the decision we were expecting. We stand by the safety and efficacy of NEBIDO, which is the market leader in many countries around the world for testosterone therap
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
4. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
5. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
6. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
7. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 2Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage 3The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 1The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 2The Michael J Fox Foundation Announces 241 5 Million in Funding to Advance Development of Drug Targets for Disease Modifying Parkinsons Disease Trea 15002 3SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 1SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 2SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 3SCOLR Pharma Inc Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 6607 4Coverage of inexpensive drugs may increase length and quality of life after heart attack 62268 1Coverage of inexpensive drugs may increase length and quality of life after heart attack 62268 2